Truist analyst Jailendra Singh lowered the firm’s price target on Hims & Hers to $33 from $39 and keeps a Hold rating on the shares as part ...

Cedar Grove Capital Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” first quarter ...

Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

CompanyOverview|NYSE:HIMS] One of the more hotly debated stocks in the market, Hims & Hers Health (NYSE: HIMS), recently made ...

The stock market has recently witnessed significant movements among key players in the technology and healthcare sectors.

Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the ...

Maxeon Solar Technologies said it is establishing an alternative network of supply-chain partners and increasing its manufacturing capabilities in the U.S. as it deals with new tariffs and trade ...

What Happened? A number of stocks jumped in the afternoon session after markets rallied sharply on news that President Trump ...